Skip to main content

Advertisement

SpringerLink
Log in

From proof to practice: innovations in total hip and total knee replacement—modern anticoagulation

  • Review Article
  • Published:
European Orthopaedics and Traumatology

Abstract

Background

Venous thromboembolism (VTE) and pulmonary embolism (PE) can be life-threatening complications after orthopaedic surgery. Last-generation oral anticoagulants like dabigatran etexilate, rivaroxaban and apixaban have the potential to become a standard in the VTE and PE prophylaxis.

Methods

Study data about the long-term efficacy and safety of dabigatran etexilate with focus in orthopaedics surgery are given and discussed by Menno Huisman (Leiden, The Netherlands), Alberto Delgado-Martinez (Jaén, Spain) and Stefano Zanasi (Florence, Italy).

Results

The study as well as the personal experience reflects the efficacy and safety of dabigatran etexilate in orthopaedic surgery in terms of prophylaxis of VTE and PE and perioperative bleeding.

Summary

Based on the actual data, the therapeutic efficacy of last-generation oral anticoagulants is not negatively influenced by their easy handling (oral administration, fixed dosage and no anticoagulation monitoring).

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR, Colwell CW, American College of Chest Physicians (2008) Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133(6 Suppl):381S–453S

    Article  PubMed  CAS  Google Scholar 

  2. Heit JA, Silverstein MD, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ (1999) Predictors of survival after deep vein thrombosis and pulmonary embolism: a population-based, cohort study. Arch Intern Med 159:445–453

    Article  PubMed  CAS  Google Scholar 

  3. Cohen AT, Agnelli G, Anderson FA, Arcelus JI, Bergqvist D, Brecht JG, Greer IA, Heit JA, Hutchinson JL, Kakkar AK, Mottier D, Oger E, Samama MM, Spannagl M, VTE Impact Assessment Group in Europe (VITAE) (2007) Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb Haemost 98:756–764

    PubMed  CAS  Google Scholar 

  4. Fitzmaurice DA, Murray E (2007) Thromboprophylaxis for adults in hospital. BMJ 334:1017–1018

    Article  PubMed  Google Scholar 

  5. Hirsh J, O'Donnell M, Eikelboom JW (2007) Beyond unfractionated heparin and warfarin: current and future advances. Circulation 116:552–560

    Article  PubMed  CAS  Google Scholar 

  6. Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H, Baanstra D, Schnee J, Goldhaber SZ (2009) Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 361:2342–2352

    Article  PubMed  CAS  Google Scholar 

  7. Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP, Kälebo P, Christiansen AV, Hantel S, Hettiarachchi R, Schnee J, Büller HR (2007) Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 5:2178–2185

    Article  PubMed  CAS  Google Scholar 

  8. Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP, Prins MH, Hettiarachchi R, Hantel S, Schnee J, Büller HR (2007) Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 370:949–956

    Article  PubMed  CAS  Google Scholar 

  9. Ginsberg JS, Davidson BL, Comp PC, Francis CW, Friedman RJ, Huo MH, Lieberman JR, Muntz JE, Raskob GE, Clements ML, Hantel S, Schnee JM, Caprini JA (2009) Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty 24:1–9

    PubMed  Google Scholar 

  10. Eriksson B, Dahl OE, Kurth AA, Hantel S, Huo MH, Hermansson K, Schnee JM, Friedman RJ (2009/2010) Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty: the RE-NOVATE II randomised trial. Pathophysiol Haemos Thromb 37(Suppl 1):A20, Abstract OC645

    Google Scholar 

  11. Huo M, Eriksson B, Dahl O, Kurth A, Hantel S, Hermansson K, Schnee J, Friedman R (2010) Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty: the RE-NOVATE II randomised trial. Haematologica 95(Suppl 2):233, Abstract 0564

    Google Scholar 

  12. EMEA (2008) CHMP Assessment Report for Pradaxa. Available at http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000829/WC500041062.pdf. Accessed 05 November 2010

  13. EMEA (2008) CHMP Assessment Report for Xarelto. Available at http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000944/WC500057122.pdf. Accessed 05 November 2010

Download references

Acknowledgements

This work was supported by Boehringer Ingelheim. Writing and editorial assistance was provided by Louise Norbury and Rebecca Gardner, PhD of PAREXEL, which was contracted by Boehringer Ingelheim for these services. The author meets criteria for authorship as recommended by the International Committee of Medical Journal Editors (ICMJE), was fully responsible for all content and editorial decisions, and was involved at all stages of manuscript development. The author received no compensation related to the development of the manuscript.

Conflict of Interest

The author is a member of the Boehringer Ingelheim Advisory Board in Germany.

Author information

Authors and Affiliations

  1. Centre for Endoprosthetic and Reconstructive Joint Surgery Orthopaedic Department, Charité, University Medicine Berlin, Berlin, Germany

    Carsten Perka

  2. Centre for Musculoskeletal Surgery Orthopaedic Department, Charité, University Medicine Berlin, Free and Humboldt-University of Berlin, Chariteplatz 1, 10117, Berlin, Germany

    Carsten Perka

Authors
  1. Carsten Perka
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Carsten Perka.

Additional information

Professor C Perka was the chairman of the satellite symposium entitled From Proof to Practice: Innovations in Total Hip and Total Knee Replacement, which was held during the 11th EFORT Congress, Madrid, Spain (2 June 2010).

Rights and permissions

Reprints and permissions

About this article

Cite this article

Perka, C. From proof to practice: innovations in total hip and total knee replacement—modern anticoagulation. Eur Orthop Traumatol 2, 3–5 (2011). https://doi.org/10.1007/s12570-011-0064-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12570-011-0064-8

Keywords

Search

Navigation